Health and Aging Brain Study: Health Disparities Tau Positron Emission Tomography (PET) Scan Study
Health and Aging Brain Study: Health Disparities Tau PET Scan Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Texas
-
Fort Worth, Texas, United States, 76107
- University of North Texas Health Science Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Enrolled in the Health and Aging Brain Study HD: Health Disparities project
- Provided consent to re-contact
- Willing and capable of undergoing PET scan of the head
Exclusion Criteria:
- Inability to provide informed consent by self or by proxy.
- Pregnant or breast feeding women*
- History of alcoholism or drug dependency/abuse within the last 2 years before screening
- Hypersensitivity to the active substance or to any of the following excipients is contraindicated: sodium dihydrogen phosphate, phosphoric acid, sodium ascorbate, ethanol (anhydrous), water for injection
- Participants may not be in this study if they do not meet the safety criteria to undergo imaging procedures.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Health and Aging Brain Study Cohort
Health and Aging Brain Study participants age 50 and older.
|
Tau PET scans are obtained using PI-2620 tracer provided by Life Medical Imaging.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health Disparities in Aging
Time Frame: Through study completion in 2 years
|
Examine the prevalence of Tau burden among a multi ethnic cohort
|
Through study completion in 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020-125
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
NCT04100889WithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5
-
NCT05637801Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia
-
NCT07573982Not yet recruitingMCI With Increased Risk for Alzheimer Disease | Alzheimer s Disease
-
NCT06597942RecruitingAlzheimer Disease | Dementia Alzheimer Type | Alzheimer&Amp;#39;s Disease (AD) | Alzheimer&Amp;Amp;#39;s Disease | Mild Alzheimer&Amp;Amp;#39;s Disease | Moderate Alzheimer&Amp;Amp;#39;s Disease | Alzheimer&Amp;#39;s Dementia
-
NCT03806478Not yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
NCT07564700Not yet recruitingEarly Onset Alzheimer Disease | Alzheimer Disease (AD)
-
NCT07459959Not yet recruiting
-
NCT07208734Enrolling by invitationAlzheimer s Disease
-
NCT07591727Not yet recruiting
-
NCT07262645Recruiting
Clinical Trials on PI-2620 tracer for Tau PET scan
-
NCT05350514CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetes, Youth Onset
-
NCT05490576Active, not recruitingNeurodegenerative Diseases | Cognitive Impairment | Head Injury Trauma | Chronic Traumatic Encephalopathy | Traumatic Encephalopathy
-
NCT03641768WithdrawnTraumatic Brain Injury | Posttraumatic Stress Disorder | Alzheimer Dementia
-
NCT02958670Active, not recruitingHealthy | Neurocognitive Disorders | Alzheimer Disease | Mild Cognitive Impairment
-
NCT06336382RecruitingLate Onset Schizophrenia | Delusional Disorder (Late Onset)
-
NCT03860857RecruitingCognitive Impairment | Alzheimer Disease | Cognitive Decline
-
NCT03754348CompletedKleine-Levin Syndrome | Narcolepsy 1